Monitoring Treatment Response to Erlotinib in EGFR‐mutated Non–small‐cell Lung Cancer Brain Metastases Using Serial O‐(2‐[18F]fluoroethyl)‐L‐tyrosine PET
暂无分享,去创建一个
M. Ruge | A. Drzezga | N. Galldiks | J. Wolf | R. Riedel | R. Büttner | C. Kobe | T. Persigehl | M. Scheffler | S. Merkelbach-Bruse | L. Nogova | S. Michels | S. Grau | Vanessa Brandes | S. Kunze | R. Fischer | D. Abdulla
[1] G. Fink,et al. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[2] Karl-Josef Langen,et al. Update on amino acid PET of brain tumours , 2018, Current opinion in neurology.
[3] Nadim Jon Shah,et al. Advances in neuro-oncology imaging , 2017, Nature Reviews Neurology.
[4] J. Landsberg,et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. , 2016, Neuro-Oncology.
[5] Ian Law,et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.
[6] Naoya Hashimoto,et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.
[7] A. Jacobs,et al. Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al. , 2013, Neuro-oncology.
[8] H. Herzog,et al. Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis , 2012, The Journal of Nuclear Medicine.
[9] G. Fink,et al. Imaging of Non— or Very Subtle Contrast-Enhancing Malignant Gliomas with [11C]-Methionine Positron Emission Tomography , 2011, Molecular imaging.
[10] U. Fuhr,et al. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.
[11] Uwe Fuhr,et al. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.
[12] R. Boellaard,et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] V. Sturm,et al. Stereotactic 125Iodine Brachytherapy for the Treatment of Singular Brain Metastases: Closing a Gap? , 2011, Neurosurgery.
[14] Sang-We Kim,et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. , 2009, Lung cancer.
[15] M. Chamberlain,et al. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas , 1988, Neurology.
[16] G. Fink,et al. Imaging of Non- or Very Subtle Contrast-Enhancing Malignant Gliomas with ( 11 C)-Methionine Positron , 2011 .